NYSE:IQVIqvia Stock Price, Forecast & News

$153.28

+1.75 (+1.15 %)

(As of 06/3/2020 03:21 PM ET)

Add

Compare

Today's Range

$150.65

Now: $153.28▼

$154.59

50-Day Range

$124.02

MA: $136.24▼

$149.52

52-Week Range

$81.79

Now: $153.28▼

$169.14

Volume45,935 shs

Average Volume1.12 million shs

Market Capitalization$29.27 billion

P/E Ratio139.35

Dividend YieldN/A

Beta1.31

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Beat the Market (BTM) Rank^™

2.5 Analyst's Opinion

Consensus Rating
Iqvia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $153.73, Iqvia has a potential upside of 0.3% from its current price of $153.28.
Amount of Analyst Coverage
Iqvia has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Iqvia has received 518 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Iqvia has received 449 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Iqvia has received 53.57% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote “Outperform” if you believe IQV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Iqvia does not currently pay a dividend.
Dividend Growth
Iqvia does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iqvia insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Iqvia is held by insiders.
Percentage Held by Institutions
88.61% of the stock of Iqvia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Iqvia are expected to grow by 27.05% in the coming year, from $5.25 to $6.67 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iqvia is 139.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iqvia is 139.35, which means that it is trading at a more expensive P/E ratio than the Business Services sector average P/E ratio of about 21.66.
Price to Earnings Growth Ratio
Iqvia has a PEG Ratio of 2.85. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Iqvia has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.49 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Commercial physical research

Sub-IndustryN/A

SectorBusiness Services

Current SymbolNYSE:IQV

Previous Symbol

CUSIPN/A

CIK1478242

Webwww.iqvia.com

Phone919-998-2000

Debt

Debt-to-Equity Ratio2.11

Current Ratio1.09

Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio139.35

Forward P/E Ratio29.20

P/E Growth2.85

Sales & Book Value

Annual Sales$11.09 billion

Price / Sales2.64

Cash Flow$12.70 per share

Price / Cash Flow12.07

Book Value$32.28 per share

Price / Book4.75

Profitability

EPS (Most Recent Fiscal Year)$5.94

Net Income$191 million

Net Margins1.93%

Return on Equity18.48%

Return on Assets5.05%

Miscellaneous

Employees67,000

Outstanding Shares190,960,000

Market Cap$29.27 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Iqvia (NYSE:IQV) Frequently Asked Questions

How has Iqvia's stock been impacted by COVID-19 (Coronavirus)?

Iqvia's stock was trading at $125.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IQV shares have increased by 22.2% and is now trading at $153.28. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iqvia?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

When is Iqvia's next earnings date?

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Iqvia.

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) released its quarterly earnings results on Tuesday, April, 28th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.02. The medical research company earned $2.75 billion during the quarter, compared to the consensus estimate of $2.74 billion. Iqvia had a net margin of 1.93% and a return on equity of 18.48%. The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.53 EPS. View Iqvia's earnings history.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its second quarter earnings guidance on Tuesday, April, 28th. The company provided earnings per share (EPS) guidance of $1.00 to $1.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.15. The company issued revenue guidance of $2.365 billion to $2.440 billion, compared to the consensus revenue estimate of $2.47 billion.

What price target have analysts set for IQV?

16 Wall Street analysts have issued 12-month price targets for Iqvia's stock. Their forecasts range from $110.00 to $195.00. On average, they anticipate Iqvia's share price to reach $153.73 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View analysts' price targets for Iqvia.

Has Iqvia been receiving favorable news coverage?

Headlines about IQV stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iqvia earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIqvia.

Are investors shorting Iqvia?

Iqvia saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,870,000 shares, a drop of 17.3% from the April 30th total of 3,470,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.5% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Auxly Cannabis Group (CBWTF). View all competitors.

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL) and Accenture (ACN).

Who are Iqvia's key executives?

Iqvia's management team includes the following people:

Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.17%), State Street Corp (4.16%), Longview Partners Guernsey LTD (3.61%), Alliancebernstein L.P. (2.56%), Janus Henderson Group PLC (2.11%) and TPG Group Holdings SBS Advisors Inc. (1.53%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Capital Research Global Investors, Canada Pension Plan Investment Board, BlackRock Inc., USS Investment Management Ltd, Melvin Capital Management LP, Eminence Capital LP, and State of Michigan Retirement System. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

Which institutional investors are buying Iqvia stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Alliancebernstein L.P., Sumitomo Mitsui Trust Holdings Inc., Korea Investment CORP, Loomis Sayles & Co. L P, Duquesne Family Office LLC, Impax Asset Management Group plc, and Global Thematic Partners LLC. View insider buying and selling activity for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $153.28.

How big of a company is Iqvia?

Iqvia has a market capitalization of $29.27 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

What is Iqvia's official website?

The official website for Iqvia is www.iqvia.com.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff